Peptide LexiconAll compounds

Telavancin (Vibativ): The Lipoglycopeptide Antibiotic Built on Vancomycin — What It Is, What Its Trials Showed and Why Its Label Carries a Boxed Warning

Telavancin is a lipoglycopeptide antibiotic made by chemically modifying vancomycin. Sold as Vibativ, it is FDA-approved for complicated skin infections and for hospital-acquired and ventilator-associated pneumonia caused by Staphylococcus aureus, with a boxed warning about kidney harm, higher deaths in pneumonia patients with poor kidney function, and harm to a fetus.

FDA-approved antibioticLipoglycopeptide (vancomycin derivative)Hospital use, intravenous

Caroline S · Published 2026-11-20

Length

C80H106Cl2N11O27P, molecular weight 1,755.6 (PubChem CID 3081362)

Sequence

Not a linear chain: the vancomycin glycopeptide core (a cross-linked seven-amino-acid backbone carrying sugars) with a decylaminoethyl side chain and a phosphonomethyl-aminomethyl group added, per the label's chemical name

Origin

Semi-synthetic, made from vancomycin. Vibativ, NDA 022110 (approved 2009-09-11) and NDA 022407 (2013-06-21) per Drugs@FDA; current label from Cumberland Pharmaceuticals, effective 2025-12-19

Last reviewed

2026-11-20

What is it good for?

Treating serious Gram-positive bacterial infections in hospitalised adults. The label covers complicated skin and skin-structure infections and hospital-acquired or ventilator-associated pneumonia caused by susceptible Staphylococcus aureus, and says it should be reserved for pneumonia when alternative treatments are not suitable. It is given by intravenous infusion.

Illustration: An empty glass conical flask with a faint copper tint at its base on a white bench, a deep green window behind.
Illustration

What it is

Telavancin is a lipoglycopeptide: vancomycin's glycopeptide core with two additions — a fatty decylaminoethyl chain and a phosphonomethyl-aminomethyl group. That is how the Vibativ label's chemical name reads ("vancomycin, N3''-[2(decylamino)ethyl]-29-[[(phosphonomethyl)amino]methyl]"), and the label calls it "a synthetic derivative of vancomycin". The core is a short chain of seven amino acids, cross-linked into a rigid cup and decorated with sugars, which is why the drug sits in this library.

Property Value Source
Formula C80H106Cl2N11O27P PubChem CID 3081362
Molecular weight 1,755.6 PubChem
Class Lipoglycopeptide antibacterial Label section 11
Made from Vancomycin (semi-synthetic) Label
Route Intravenous infusion over 60 minutes Label section 2

How it acts. The label's microbiology section gives two actions: telavancin "inhibits cell wall biosynthesis by binding to late-stage peptidoglycan precursors, including lipid II", and it "binds to the bacterial membrane and disrupts membrane barrier function". The first is the action it shares with its parent; the second is what the label adds for telavancin.

Its relatives in the library. Vancomycin is the parent. Two other approved lipoglycopeptides carry their own entries: dalbavancin and oritavancin.

What the trials showed

Skin infections. The label reports two identical randomised, double-blind trials comparing telavancin 10 mg/kg once daily with vancomycin 1 g twice daily for 7 to 14 days in adults with complicated skin and skin-structure infections where MRSA was suspected or confirmed. The all-treated population was 1,794 patients; major abscess (42–44%) and deep or extensive cellulitis (35–37%) made up about three in four infections (label Table 9).

Population Trial 1: telavancin Trial 1: vancomycin Trial 2: telavancin Trial 2: vancomycin
All treated 72.5% (309/426) 71.6% (307/429) 74.7% (342/458) 74.0% (356/481)
Clinically evaluable 84.3% (289/343) 82.8% (288/348) 83.9% (302/360) 87.7% (315/359)

Read across the table, the cure rates sit within a few points of vancomycin in every cell; in the clinically evaluable group of Trial 2, vancomycin's figure is the higher one.

Hospital and ventilator pneumonia. Two further identical trials compared the same regimens for 7 to 21 days. The label states that all-cause mortality was evaluated "because there is historical evidence of treatment effect for this endpoint". Its Table 12 gives 28-day mortality in patients with at least one Gram-positive respiratory pathogen:

Group Trial 1: telavancin Trial 1: vancomycin Trial 2: telavancin Trial 2: vancomycin
All patients 28.7% (N=187) 24.3% (N=180) 24.3% (N=224) 22.3% (N=206)
CrCl ≤ 50 mL/min 41.8% (N=63) 35.4% (N=68) 43.9% (N=53) 29.6% (N=58)
CrCl > 50 mL/min 22.0% (N=124) 17.6% (N=112) 18.2% (N=171) 19.3% (N=148)

The kidney-impairment row is the source of the boxed warning: in both trials more patients with poor kidney function died on telavancin, by 6.4 and 14.3 percentage points. The confidence intervals the label prints for those differences both cross zero, so each trial alone does not establish the gap; the label's warning rests on the pattern, and the label reserves the pneumonia use for when alternatives are not suitable.

What is not established: any advantage over vancomycin in cure rate, and any use outside the two labelled infection types.

Risks the label lists

  • Boxed warning: increased mortality in pneumonia patients with creatinine clearance of 50 mL/min or less; new-onset or worsening kidney impairment (kidney function is monitored in all patients); possible fetal harm, from animal reproduction studies.
  • Common reactions: taste disturbance, nausea, vomiting and foamy urine in the skin-infection trials; diarrhoea in the pneumonia trials (10% or more of patients).
  • Other warnings: infusion-related reactions (hence the 60-minute infusion), Clostridioides difficile-associated diarrhoea, and QTc prolongation, with the label advising avoidance in patients at risk.

Where it stands

Telavancin is a prescription hospital antibiotic in the US. Drugs@FDA holds two Vibativ applications — NDA 022110, original approval 11 September 2009, and NDA 022407, original approval 21 June 2013 — and on 2026-11-20 listed one Vibativ product as discontinued and the rest as prescription products; this entry does not infer why. The current label, effective 19 December 2025, names Cumberland Pharmaceuticals as the company to report adverse reactions to. The label dose is 10 mg/kg once every 24 hours, adjusted to 7.5 mg/kg every 24 hours at a creatinine clearance of 30–50 mL/min and lowered further below that.

Other peptide antibiotics in the library work differently: daptomycin is a lipopeptide that disrupts the membrane, and polymyxin B targets Gram-negative bacteria that telavancin does not cover.

Sources opened 2026-11-20: Vibativ label (openFDA, effective 2025-12-19: sections 1, 2, 5, 6, 11, 14 incl. Tables 9, 10, 12); Drugs@FDA records for NDA 022110 and NDA 022407; PubChem CID 3081362 (properties); PubMed E-utilities and ClinicalTrials.gov API v2 counts.

What the research shows

Cures complicated skin infections about as often as vancomycin

Two identical randomised double-blind trials, 1,794 patients in the all-treated population: clinical cure 72.5% v 71.6% (Trial 1) and 74.7% v 74.0% (Trial 2) against vancomycin (Vibativ label, Table 10)

Treats staph pneumonia acquired in hospital or on a ventilator

Two identical randomised double-blind trials against vancomycin; 28-day all-cause mortality 28.7% v 24.3% and 24.3% v 22.3% in patients with a Gram-positive pathogen; higher in those with CrCl ≤50 mL/min (label, Table 12)

Acts on the bacterial cell wall and membrane

Label section 12.4: binds late-stage peptidoglycan precursors including lipid II, and binds the bacterial membrane, disrupting its barrier function (laboratory mechanism)

Bars show how much of the evidence is in humans, not how well anything works.

Where it stands

United States

Prescription antibiotic; Drugs@FDA lists one Vibativ product on NDA 022110 as discontinued and others as prescription (read 2026-11-20). Boxed warning for higher mortality in pneumonia with moderate or severe kidney impairment, nephrotoxicity and fetal risk.

How it is given

10 mg/kg by intravenous infusion over 60 minutes every 24 hours, 7 to 14 days for skin infections and 7 to 21 days for pneumonia, adjusted for kidney function (label section 2).

Published record

PubMed: 474 records for 'telavancin'; ClinicalTrials.gov: 17 studies (2026-11-20).

Frequently asked questions

What is telavancin?

An intravenous hospital antibiotic made by chemically modifying vancomycin. It belongs to the lipoglycopeptides, glycopeptide antibiotics that carry a fatty side chain. It is sold in the US as Vibativ.

Why is telavancin in a peptide library?

Because its core is a glycopeptide: the same cross-linked chain of seven amino acids, carrying sugars, that forms vancomycin. Telavancin adds a fatty decylaminoethyl chain and a phosphonate group to that core.

What infections is telavancin approved for?

In adults, complicated skin and skin-structure infections caused by susceptible Gram-positive bacteria, and hospital-acquired or ventilator-associated pneumonia caused by susceptible Staphylococcus aureus. For pneumonia the label says it should be reserved for when alternatives are not suitable.

What does the boxed warning say?

That pneumonia patients with moderate or severe kidney impairment (creatinine clearance 50 mL/min or less) had higher mortality on telavancin than on vancomycin, that new or worsening kidney impairment has occurred, and that it may cause fetal harm, based on animal reproduction studies.

What dose does the label state?

10 mg/kg by intravenous infusion over 60 minutes once every 24 hours, for 7 to 14 days in skin infections and 7 to 21 days in pneumonia, with lower or less frequent doses when kidney function is reduced. Dosing is set by the treating hospital team.

How does telavancin compare with vancomycin in the trials?

In the skin-infection trials cure rates were within about one percentage point of vancomycin in the all-treated population. In the pneumonia trials, deaths at day 28 were numerically higher on telavancin, and clearly so among patients with poor kidney function, which is what the boxed warning reflects.